{"entity":{"id":"nct07109219","kind":"trial","name":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","aka":[],"tldr":"A phase 1/2 trial of AZD4512 in acute lymphoblastic leukaemia, run by AstraZeneca, now recruiting.","summary":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT07109219 by AstraZeneca, with 83 participants planned, started 2025-11-12 and due to reach its primary completion in 2028-04-28. Interventions recorded: AZD4512 monotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07109219","url":"https://clinicaltrials.gov/study/NCT07109219"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["azd4512"],"companies":["astrazeneca","fortrea"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07109219","phase":"1/2","setting":"A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia","sponsor":"AstraZeneca","enrolled":83,"outcomes":[]},"route":"/trials/nct07109219/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"drug":[{"id":"azd4512","kind":"drug","name":"AZD4512","route":"/drugs/azd4512/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"fortrea","kind":"company","name":"Fortrea","route":"/companies/fortrea/"}]}}